CeraFlex PFO Closure System Post-Market Clinical Follow-up Study: A Multi-center, Prospective, Observational, Post-market Study

Status: Recruiting
Location: See all (10) locations...
Intervention Type: Device
Study Type: Observational
SUMMARY

The purpose of this study is to compile real-world data on patient outcomes and evaluate the procedural success and performance of the CeraFlex™ PFO Closure System.

Eligibility
Participation Requirements
Sex: All
Minimum Age: 18
Maximum Age: 85
Healthy Volunteers: f
View:

• Patient with indication(s) for PFO Occluder Closure in the Instruction For Use (IFU):

‣ Confirmed PFO by medical examinations;

⁃ Associated with recurrent migraine/headache or TIA or cryptogenic stroke.

• Patient characteristics consistent with the corresponding IFU \& Device Size Selection:

‣ Measure the distance from the defect to the aorta root;

⁃ Measure the distance from the defect to the superior vena cava (SVC) rim; select a device with the radius of the right disc that will not exceed the lesser of these two distances.

• Patients who are willing to comply with all study procedures and be available for the duration of the study.

• Patients or legally authorized representative(s) who are willing and capable of providing informed consent.

Locations
Other Locations
Germany
Kardiologisch-Angiologische Praxis - Herzzentrum Bremen
RECRUITING
Bremen
Heart Center Dresden
NOT_YET_RECRUITING
Dresden
Hospital Fürth
RECRUITING
Fürth
Kath. Marienkrankenhaus gGmbH
RECRUITING
Hamburg
Universitätsklinikum Hamburg-Eppendorf (UKE)
RECRUITING
Hamburg
German Heart Center Leipzig
RECRUITING
Leipzig
Klinikum St. Georg gGmbH Leipzig
NOT_YET_RECRUITING
Leipzig
German Heart Center Munich
RECRUITING
Munich
Herzzentrum Trier
RECRUITING
Trier
University clinic Tübingen
RECRUITING
Tübingen
Contact Information
Primary
KaDirr Shemsi, PM
KaDirr@lifetechmed.com
17621309203
Time Frame
Start Date: 2023-11-03
Estimated Completion Date: 2028-12
Participants
Target number of participants: 180
Sponsors
Leads: Lifetech Scientific (Shenzhen) Co., Ltd.

This content was sourced from clinicaltrials.gov